All In Biotech

Free tool

FAERS Monitor: Atorvaliq

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 213260 or its brand name (Atorvaliq, Atorvastatin Calcium). Reports on generic versions are filed under their own applications.

Reports

21

Serious

12

57% of reports

Hospitalization

5

Death reported

1

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • off label use3
  • dizziness2
  • eye pain2
  • headache2
  • hypervolaemia2
  • pain2
  • peripheral swelling2
  • product dose omission issue2
  • pruritus2
  • vision blurred2
  • weight decreased2
  • abdominal pain1
  • abdominal pain upper1
  • accidental overdose1
  • acute kidney injury1

Reports by year received

View as table
YearReports
20221
20231
20242
202511
20266

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,138 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
hypervolaemia2405.5108.5453
eye pain235.59.537
accidental overdose127.44.06
vision blurred214.63.914
peripheral swelling213.03.512
weight decreased27.21.95
product dose omission issue26.81.85
acute kidney injury16.51.01
pruritus25.21.43
abdominal pain upper14.90.70
abdominal pain14.30.60
dizziness24.01.12
off label use33.41.23
pain23.30.91
headache23.20.91

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.